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Human bone marrow-derived mesenchymal stromal cells (MSCs) obtained from aged patients are prone to senesce and diminish
their differentiation potential, therefore limiting their usefulness for osteochondral regenerative medicine approaches or to study
age-related diseases, such as osteoarthiritis (OA). MSCs can be transduced with immortalizing genes to overcome this
limitation, but transduction of primary slow-dividing cells has proven to be challenging. Methods for enhancing transduction
efficiency (such as spinoculation, chemical adjuvants, or transgene expression inductors) can be used, but several parameters
must be adapted for each transduction system. In order to develop a transduction method suitable for the immortalization of
MSCs from aged donors, we used a spinoculation method. Incubation parameters of packaging cells, speed and time of
centrifugation, and valproic acid concentration to induce transgene expression have been adjusted. In this way, four
immortalized MSC lines (iMSC#6, iMSC#8, iMSC#9, and iMSC#10) were generated. These immortalized MSCs (iMSCs) were
capable of bypassing senescence and proliferating at a higher rate than primary MSCs. Characterization of iMSCs showed that
these cells kept the expression of mesenchymal surface markers and were able to differentiate towards osteoblasts, adipocytes,
and chondrocytes. Nevertheless, alterations in the CD105 expression and a switch of cell fate-commitment towards the
osteogenic lineage have been noticed. In conclusion, the developed transduction method is suitable for the immortalization of
MSCs derived from aged donors. The generated iMSC lines maintain essential mesenchymal features and are expected to be
useful tools for the bone and cartilage regenerative medicine research.
1. Introduction
Human bone marrow-derived mesenchymal stromal cells
(MSCs) are a promising cell source for bone and cartilage
therapies due to their self-renewal capacity and multipotency
[1–4]. However, culture-expanded MSCs progressively lose
these capacities, which is a major limitation for research
[2–5]. Moreover, both proliferative and differentiation
potentials of MSCs decrease with donor aging [3, 6, 7]. As a
result, research involving MSCs derived from aged donors
is limited by both in vitro expansion-induced senescence
and donor-related reduction of proliferation. This is a major
bottleneck for research on MSC-based regeneration of skele-
tal tissues in age-related chronic joint diseases, with
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osteoarthritis (OA) being one of the most common and dis-
abling ones [3, 8].
This proneness to senescence of aged MSCs may be over-
come by immortalization, which requires repression of p53-
and Rb-mediated pathways and telomere maintenance. Cell
immortalization can be achieved by either transduction of
immortalizing genes like simian virus 40 large T antigen
(SV40LT) [9, 10] or human papillomavirus E6/E7 gene [11]
which promote cell cycle progression, or human telomerase
reverse transcriptase (hTERT) which prevents telomeres
shortening [12–14]. Transduction of single SV40LT/E6/E7
or hTERT can fail to immortalize primary human cells [15,
16] and specifically MSCs [14, 17–19], while the combination
of SV40LT and hTERT has been shown to be useful for gen-
erating immortalized MSC lines [17]. Nevertheless, most
immortalized MSC lines have been generated from healthy
and/or young donors [9, 11, 12, 14], whereas “aged” and “dis-
eased” MSC lines are still lacking. The underlying cause
might be that retroviral transduction is limited by their inef-
ficiency in infecting aged and/or diseased donor-derived
MSCs because they are slow-dividing cells [20].
Therefore, strategies to enhance infection efficiency
should be employed. One of these strategies is spinoculation,
which has been used during decades to improve viral infec-
tion of several types of cells in vitro [21–34] (Table 1),
although the process responsible for spinoculation-induced
enhancement of infection has not been discovered yet [33].
However, it is known that the enhancement of infection
induced by spinoculation is cell type-dependent [20, 25]
and also related to the speed of centrifugation [33] in a cell
type-dependent manner [23]. Therefore, spinoculation
parameters must be optimized for each transduction system
(virus and target cell type). Since spinoculation-induced
enhancement of infection is also related to virus concentra-
tion, it could be possible to increase it by prolonging the post-
transfection incubation of packaging cells before harvesting
[22, 28, 32, 33]. As virus half-life at 37°C is shorter than at
32°C, packaging cell incubation and centrifugal infection
may need to be performed at 32°C [21, 27–29].
For greater enhancement of infection, chemical adjuvants
for transduction and inductors of transgene expression can
be used. Hexadimethrine bromide (HDMB, also known as
Polybrene) is the most usual adjuvant for retroviral infection
but should be used over short application times and at low
concentrations due to the high cellular toxicity [22, 35].
The combination of HDMB and spinoculation may have a
synergistic effect in enhancing infection [36], but it has been
proposed that centrifugation-induced stress produced during
spinoculation also might increase cell susceptibility to
HDMB toxicity [35].
The histone deacetylase inhibitor valproic acid (VPA, 2-
propyl-valeric acid) could be used for transgene expression
induction [37, 38]. VPA not only prevents the transcriptional
silencing of genes [39] but also reduces cell proliferation [39,
40] and might even exert a negative [39] or positive effect on
cell viability, depending on the concentration and cell type
[37, 40]. Thus, the concentration needs to be adjusted in
order to enhance transgene expression without affecting cell
viability and proliferation.
Taking all this information into account, the aim of this
study was to develop an efficient method for immortalization
of slow-dividing cells, like MSCs from aged donors, without
losing the parental phenotype.
2. Materials and Methods
2.1. Isolation and Culture of Human Bone Marrow-Derived
Mesenchymal Stromal Cells (MSCs). The present study was
reviewed and approved by the Ethics Committee of Research
from A Coruña-Ferrol, Spain (2016/588). The bone marrow
samples were collected from patients who underwent ortho-
paedic surgery, after obtaining written informed consent
from each donor: eight patients with hip OA (ages ranging
from 45 to 94 y.o., five males and three females) and three
patients with hip fracture but no OA (ages ranging from 65
to 88 y.o., two males and one female). The bone marrow of
femoral heads was washed with Dulbecco’s Modified Eagle’s
Medium (DMEM; Lonza, Madrid, Spain) supplemented with
5% foetal bovine serum (FBS, Gibco, Thermo Fisher Scien-
tific, Madrid, Spain) and 1% penicillin/streptomycin (P/S,
Gibco, Thermo Fisher Scientific) (5%FBS/DMEM). After
centrifugation at 430 ×g for 10min, cells were plated in
adherent culture dishes (Costar Corning Incorporated, New
York, USA) and grown in DMEM supplemented with 20%
FBS and 1% P/S (20%FBS/DMEM) at 37°C [41]. Subcultur-
ing was performed when cell confluence reached 80-90%,
including a 15min preplating technique [42] at the first and
second passages (Figure 1). Obtained MSCs were used for
spinoculation experiments at the third to fifth passages.
2.2. MSC Spinoculation with Retrovirus Produced by Phoenix
Cells. Phoenix amphotropic (ATCC® CRL-3213™) cells [43]
were plated on 100mm adherent culture dishes (Costar
Corning Incorporated), grown in 10% FBS/DMEM and
transfected employing one out of two plasmids, both
obtained from Addgene: pBABE-puro-SV40LT (plasmid
#13970), deposited by Thomas Roberts [44], or pBABE-
hygro-eGFP-hTERT (plasmid #28169), deposited by Kath-
leen Collins [45]. For each culture dish, 10μg of plasmid were
mixed with Opti-MEM (Gibco, Thermo Fisher Scientific) up
to a volume of 970μl. Then, 30μl of X-tremeGENE HP DNA
Transfection Reagent (Roche, Sigma-Aldrich Química S.A.)
were added, and this mixture was incubated for 25 minutes
at room temperature. Thereafter, the mixture was added to
culture dishes in a dropwise manner. Transfected Phoenix
cells were incubated at 37°C during 24 hours, whereupon
the culture medium was changed and cells were incubated
at 32°C for retrovirus production [21, 29].
After incubation at 32°C, the supernatant was collected
and filtered through a 0.45μm pore size membrane filter
(Millipore, Burlington, Massachusetts, USA). 8μg of HDMB
(Sigma-Aldrich Química S.A.) was added per ml of retroviral
supernatants [28, 46], and this mixture was employed for the
infection of MSCs at 70% confluence in 6-well adherent cul-
ture dishes (Costar Corning Incorporated) (Figure 1). No
viruses were added to one well of each dish, which was used
as a negative control for antibiotic selection.
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Different MSC spinoculation experiments were per-
formed, including coinfections with SV40LT and hTERT ret-
roviruses as well as infections with single SV40LT or hTERT
viruses. A volume of 1.5ml retroviral supernatant was added
to each well. Two centrifugation speeds (1000 and 800 ×g)
and three time-points (60, 45, and 30 minutes) were assayed
for spinoculation (Table 2), which was performed at 32°C.
After spinoculation, MSCs were incubated for 4 hours at
37°C, and after, retroviral supernatants were replaced by a
fresh culture medium with different concentrations of VPA
(Cayman Chemical Company, Ann Arbor, Michigan, USA)
[37] (Table 2). After three days, the culture medium was
replaced by a selection culture medium containing 2.5μg/ml
puromycin (Thermo Fisher Scientific) or 75μg/ml
Table 2: Variations of the transduction method assayed, detailing retrovirus employed, culture conditions for Phoenix cells, spinoculation
conditions, and VPA concentration employed to induce transgene expression.
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Figure 1: Human MSC immortalization method, including SV40LT and hTERT retroviruses produced by Phoenix cells, spinoculation with
HDMB, and transgene expression induction by VPA.
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hygromycin (AMRESCO, VWR International, Radnor,
Pennsylvania, USA) (Figure 1).
2.3. Optimization of VPA Concentration. VPA was added to
the culture medium after retroviral infection to induce trans-
gene expression. To determine the optimal VPA concentra-
tion, cell viability measurements were carried out in three
MSC transduction experiments with SV40LT retrovirus. Cell
viability was determined by employing Cell Counting Kit-8
(CCK-8) (Sigma-Aldrich Química S.A.) (1) before spinocula-
tion; (2) after spinoculation, just before VPA addition; (3)
after three-day incubation with a culture medium containing
0.5, 1, 2, 3, or 5mMVPA; and (4) after selection of transduced
cells in a culture medium containing 2.5μg/ml puromycin.
Absorbance measurements were performed in triplicate using
a NanoQuant Infinite M200 microplate reader (Tecan Ibérica
Instrumentación S.L., Barcelona, Spain) with a measurement
wavelength of 450nm and a reference wavelength of 650nm,
following the manufacturer’s instructions.
2.4. Testing SV40LT and eGFP-hTERT Nuclear Expression in
TransducedMSCs. TransducedMSCs seeded in 8-well cham-
ber slides (Millipore) were washed with phosphate-buffered
saline (PBS; Dako, Agilent Technologies Spain S.L., Barcelona,
Spain), fixed with 4% paraformaldehyde (Sigma-Aldrich
Química S.A.), quenched with 1% glycine, permeabilized with
0.5% Triton X-100 (Sigma-Aldrich Química S.A.), and
blocked with 4% bovine serum albumin (Sigma-Aldrich
Química S.A.). Subsequent incubation with primary antibod-
ies was performed at 4°C overnight: SV40LT (SV40LT clone
Pab 108; 1 : 100; Santa Cruz Biotechnology, Dallas, Texas,
USA) and GFP (anti-GFP conjugated to AF488; 1 : 500; A-
21311, Invitrogen, Thermo Fisher Scientific).
After three washes in PBS, cells were incubated with a
fluorescent goat anti-mouse secondary antibody (A-11032;
1 : 1000; Invitrogen, Thermo Fisher Scientific) at room tem-
perature for one hour. After three additional washes in PBS,
two-minute incubation with Hoechst (bisBenzimide H
33342 trihydrochloride, Sigma-Aldrich Química S.A.) was
performed. Slides were mounted with Glycergel aqueous
mounting medium (Dako, Agilent Technologies Spain S.L.)
and observed by employing an Olympus BX61 fluorescence
microscope (Olympus Iberia S.A., Barcelona, Spain) coupled
to an Olympus DP70 digital camera (Olympus Iberia S.A.).
Immunostained SV40LT was identified by red fluorescence
while enhanced Green Fluorescent Protein-hTERT (eGFP-
hTERT) was identified by green fluorescence. Fluorescence
micrographs were obtained employing the cellSens Dimen-
sion software (Olympus Iberia S.A.).
2.5. Analysis of Morphology and Proliferative Capacity of
Transduced MSCs. Cells were observed with a Nikon Eclipse
TS100 inverted microscope (Nikon Instruments Europe B.V.,
Amsterdam, Netherlands) coupled to a XM Full HD digital
camera (Hangzhou Xiongmai Technologies (XM), Hang-
zhou, China). iMSC proliferation was calculated as cumula-
tive population doublings (PDs) at each passage, following
the formula in Equation (1), where Nf is the final cell num-
ber, Ni is the initial cell number, and log is the natural loga-
rithm [46]. The number of accumulated generations per
days in culture was analysed by regression for each cell line.
Generation time was calculated for each cell line at each pas-
sage as the number of PDs per day, and generation times of
all cell lines were compared.
PD = logNf ‐logNilog 2 , ð1Þ
Histochemical staining for senescence-associated β-
galactosidase activity was performed for each cell line after
reaching more than 100 PDs at three different passages, using
the Senescence Cell Histochemical Staining kit (Sigma-
Aldrich Química S.A.). After 16 hours of incubation, β-galac-
tosidase-positive and β-galactosidase-negative cells were
counted on ten random microscope fields and percentage
of senescent cells was calculated. Results are provided as
mean percentage of senescent cells ± standard error. Senes-
cence values of iMSCs and primary MSCs were compared.
2.6. Testing the Preservation of MSC Surface Marker
Expression in Transduced MSCs. Mesenchymal stromal cell-
positive (CD29, CD44, CD73, CD90, and CD105) and mes-
enchymal stromal cell-negative (CD34 and CD45) surface
marker expression was analysed by flow cytometry in pri-
mary and transduced MSCs. For comparison with another
MSC line, the expression of the aforementioned surface
markers was also analysed in the 3a6 line [47], kindly pro-
vided by Dr. Hung’s group. Cells were trypsinized, washed
twice in Fluorescence Activated Cell Sorting (FACS) buffer
(BD Biosciences, Madrid, Spain), and incubated at 4°C for
45minutes with the following antibodies: fluorescein isothio-
cyanate (FITC) isotype (clone ICIG1 (1 : 50), Immunostep
S.L., Salamanca, Spain), phycoerythrin (PE) isotype (clone
B11/6 (1 : 50), Immunostep S.L.) PE/Cy5 isotype (clone 1F8
(1 : 25), Abcam, Cambridge, UK), PE-conjugated anti-
human CD29 (clone VJ1/14 (3 : 50), Immunostep S.L.), PE-
conjugated anti-human CD34 (clone 581 (2 : 25), BD Phar-
mingen, Madrid, Spain), FITC-conjugated anti-human
CD44 (clone IM7 (1 : 50), BD Pharmingen), FITC-
conjugated anti-human CD45 (clone D3/9 (3 : 50), Immuno-
step S.L.), PE-conjugated anti-human CD73 (clone AD2
(3 : 50) Immunostep S.L.), PE/Cy5-conjugated anti-human
CD90 (clone 5E10 (1 : 50) Immunostep S.L.), and FITC-
conjugated anti-human CD105 (clone SN6 (1 : 50), AbD
Serotec, Bio-Rad Laboratories, S.A., Madrid, Spain). After
incubation, cells were washed, resuspended in FACS
buffer, and transferred to polypropylene tubes (NUNC,
VWR International). Acquisition was made with a BD
FACSCalibur flow cytometer (BD Biosciences), and data
obtained was analysed using BD CellQuest Pro software
(BD Biosciences). For each assay, a minimum of 105 cell
events were acquired and analysed.
2.7. Testing the Preservation of MSC Multipotency in
Transduced MSCs. Primary and transduced MSCs were
differentiated towards osteoblasts, adipocytes, and
chondrocytes.
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2.7.1. Osteogenesis. For osteogenic cell differentiation, two
types of experiments were carried out: monolayer differenti-
ation and three-dimensional osteogenesis through endo-
chondral ossification. For monolayer differentiation, 2 × 104
cells were plated on 8-well chamber slides (Millipore) for his-
tology and 105 cells were plated on 6-well plates (Costar
Corning Incorporated) for molecular analysis. For histology,
cells were fixed with 4% paraformaldehyde (Sigma-Aldrich
Química S.A.) and stained with Alizarin Red after growing
for 21 days in hMSC Ostegenic Differentiation Medium
(Lonza) and 20%FBS/DMEM (as the control).
For three-dimensional differentiation, cell aggregates
were formed by the hanging drop method, seeding drops
containing 5 × 105 cells on a lid of a 90mm Petri dish filled
with PBS (MP Biomedicals, Thermo Fisher Scientific). After
two days, the aggregates were transferred to suspension
culture system in propylene tubes (J.C. Catalán S.L., Barce-
lona, Spain) and maintained for 14 days in hMSC Chon-
drogenic Differentiation Medium (Lonza) with 10 ng/ml
TFG-β3 (ProSpec-Tany TechnoGene) and then in hMSC
Ostegenic Differentiation Medium (Lonza) for 21 days,
or in 20%FBS/DMEM (as the control) for 35 days [48].
Aggregates were stained with Alizarin Red and Von Kossa
to evaluate mineralization level and with Masson’s Tri-
chrome and Safranin O to investigate the presence of
remaining chondrogenic features.
2.7.2. Adipogenesis. For adipogenic cell differentiation exper-
iments, 2 × 104 cells were plated on 8-well chamber slides
(Millipore) for histology and 105 cells were plated on 6-well
plates (Costar Corning Incorporated) for molecular analysis.
Cells were grown for 21 days in hMSC Adipogenic Differen-
tiation BulletKit Medium (Lonza) or StemPro Adipogenesis
Differentiation Kit (Gibco, Thermo Fisher Scientific) and
20%FBS/DMEM (as the control). For histological analysis,
cells were fixed with 4% paraformaldehyde (Sigma-Aldrich
Química S.A.) before Oil Red O staining was performed.
Slides were mounted with Glycergel aqueous mounting
medium (Dako, Agilent Technologies Spain S.L.).
2.7.3. Chondrogenesis. For chondrogenic cell differentiation
experiments, three-dimensional cell culture was used [49].
Cell aggregates were formed by the hanging drop method
and maintained for 21 days in hMSC Chondrogenic
Differentiation Medium (Lonza) with 10ng/ml human trans-
forming growth factor β-3 (TFG-β3) (ProSpec-Tany Tech-
noGene, Rejovot, Israel) or in 20%FBS/DMEM (as the
control). After that, aggregates were fixed with 4.0% formal-
dehyde (Panreac Química S.L.U., Barcelona, Spain), embed-
ded in paraffin (Merck Millipore, Merck KGaA, Darmstadt,
Germany), and cut in a microtome for histology. Extracellu-
lar matrix histological and immunohistochemical staining
techniques were performed to assess the presence and nature
of proteoglycans (Safranin O staining and aggrecan immu-
nostaining) and collagen fibers (Masson’s Trichrome
staining and type II collagen immunostaining). Before
immunostaining, cell aggregates were pretreated with chon-
droitinase ABC (Sigma-Aldrich Química S.A.). Incubations
with primary antibodies anti-collagen II (clone 5B2.5
(1 : 25), Thermo Fisher Scientific) and anti-aggrecan (clone
BC-3 (1 : 50), Abcam) were performed overnight. Dako
REAL EnVision Detetion System (Dako, Agilent Technolo-
gies Spain S.L.) was used for immunostaining visualization,
and slides were mounted with DPX mounting medium (Sur-
gipath, Leica Microsistemas S.L., Spain).
2.7.4. Histological and Immunohistological Assessment. All
slides were observed employing an Olympus BX61 micro-
scope (Olympus Iberia S.A.) coupled to an Olympus DP70
digital camera (Olympus Iberia S.A.). Micrographs were
obtained employing the cellSens Dimension software (Olym-
pus Iberia S.A.). Quantitative analysis of stained areas and
intensity of staining was carried out as previously described
[41] employing the ImageJ software (National Institutes of
Health, Bethesda, USA). The percentage of stained area was
expressed as mean ± standard error. Optical density (OD)
was calculated as OD = log ðmax intensity/mean intensityÞ,
where log is the natural logarithm.
2.7.5. Molecular Analysis. RNA from nondifferentiated cells
as well as adipogenic and osteogenic cell differentiations
was isolated by employing TRIzol Reagent (Thermo Fisher
Scientific) and chloroform (Sigma-Aldrich Química S.A.)
and precipitated with isopropanol (Sigma-Aldrich Química
S.A.). Reverse transcription was carried out by using Super-
Script VILO cDNA Synthesis kit (Thermo Fisher Scientific)
in an Applied Biosystems Veriti 96-Well Thermal Cycler
(Thermo Fisher Scientific), following the manufacturer’s
instructions. Quantitative real-time PCR (qPCR) was per-
formed in a LightCycler1 480 Instrument (Roche), employ-
ing LightCycler 480 SYBR Green I Master (Roche) in
addition to primers shown in Table 3. Tyrosine 3-monooxy-
genase/tryptophan 5-monooxygenase activation protein zeta
(YWHAZ) was employed as a reference gene. Data analysis
was done using the LightCycler 480 Relative Quantification
software (Roche) and relative gene expression levels (REL)
were calculated employing qbase+ software (Biogazelle, Zwij-
naarde, Belgium). Normalized gene expression values were
scaled to the sample with the highest expression for each
gene. Osteogenesis- and adipogenesis-related gene expres-
sion levels are shown for each cell line as mean ± standard
error, while transgene expressions are shown as mean ±
standard error of their level of expression in four lines of
transduced MSCs versus the four populations of primary
MSCs from which they were derived.
2.8. Testing Colony Formation Ability and Oncogenic
Potential of Transduced MSCs. To assess the colony forma-
tion ability of the transduced MSCs, cells were seeded in 6-
well culture dishes (Costar Corning Incorporated) at a den-
sity of 500 cells per well and maintained in culture for one
week. After that, the dishes were washed with PBS, fixed with
4% paraformaldehyde (Sigma-Aldrich Química S.A.) and
stained with 0.1% crystal violet (Sigma-Aldrich Química
S.A.). Micrographs were taken employing a Nikon SMZ
745T stereomicroscope (Nikon Instruments Europe B.V.,
Amsterdam, Netherlands) coupled to a Nikon DS-Fi2 digital
camera (Nikon Instruments Europe B.V.).
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In addition, the soft agar colony formation assay [50] was
performed to investigate the oncogenic potential of the trans-
ducedMSCs. For each cell line, 15000 cells were inoculated in
0.375% agar (Sigma-Aldrich Química S.A.) and layered on
top of 0.5% agar layer in 12-well culture dishes (Costar Corn-
ing Incorporated) (3750 cells/well). Cells were incubated for
14 days at 37°C with 5% CO2. Colonies were observed and
photographed using a Nikon Eclipse TS100 inverted micro-
scope (Nikon Instruments Europe B.V.) coupled to a XM Full
HD digital camera (Hangzhou Xiongmai Technologies
(XM), Hangzhou, China).
Additionally, the level of expression of tumor-related
genes was quantified in primary MSCs, transduced MSCs,
and the osteosarcoma cell line 143B by quantitative real time
PCR (qPCR). RNA isolation, qPCR, and data analysis were
performed as previously described. Normalized gene expres-
sion values for each gene were scaled to the cell line 143B,
employed as a positive control of oncogenic potential.
2.9. Statistical Analysis. Results were analysed using the
Kruskal-Wallis and Mann–Whitney tests, employing Prism
software (v5, GraphPad, Inc.). Differences between groups
were considered significant if p value < 0.05.
3. Results
3.1. MSC Spinoculation with Retrovirus Produced by Phoenix
Cells. Variations of several parameters for the transduction
method were assayed for immortalization of primary
human MSCs (Table 2). The spinoculation at 1000 ×g for
60minutes with SV40LT and hTERT retrovirus (coinfec-
tion) produced by transfected Phoenix cells for 24 hours
caused cell death of almost all cell population. Same result
was obtained with hTERT retrovirus alone. A decrease in
cell death was observed when employing SV40LT retrovirus
alone, but even so spinoculation resulted in SV40LT-
transduced MSCs (T-MSCs) with very low efficiency,
and only with VPA induction of transgene expression
(experiments 1 and 2).
Even when lowering centrifugation time to 45minutes,
spinoculation at 1000 ×g still produced cell death of most
MSCs (experiment 3). Conversely, lowering centrifugation
speed to 800 ×g resulted in much more cell survival after spi-
noculation (experiment 4). When prolonging incubation
time for retrovirus production to 48 hours, the transduction
efficiency was highly improved and a larger population of
T-MSCs was obtained (experiment 4). A shorter time of cen-
trifugation (30 minutes) reduced transduction efficiency and
did not improve cell survival (experiment 5). Established
parameters (48-hour incubation of transfected Phoenix cells
for retrovirus production, spinoculation at 800 ×g for
45minutes, and transgene expression induction by 2mM
VPA addition) were successfully employed for SV40LT
transduction of MSCs derived from six donors (experiments
4, 6, and 8). Puromycin-selected T-MSCs had grown enough
to be trypsinized within one week after selection.
Table 3: List of primers employed for quantitative real time PCR (qPCR) analysis.
Gene
Reference
sequence Forward primer (5





Homo sapiens runt-related transcription
factor 2 (RUNX2)
NM_001024630.4 TTACTTACACCCCGCCAGTC TATGGAGTGCTGCTGGTCTG
Homo sapiens Sp7 transcription
factor (SP7)
NM_001173467.2 TCCCCTGTTGCCATGGTTAT CCACCCATTCTTCAGGAGGT
Homo sapiens bone gamma-
carboxyglutamate protein (OCN)
NM_199173.5 GGCGCTACCTGTATCAATGG TCAGCCAACTCGTCACAGTC
Homo sapiens adiponectin, C1Q and












Homo sapiens HRas protooncogene,
GTPase (HRAS)
NM_005343.4 TGCCATCAACAACACCAAGT ACGTCATCCGAGTCCTTCAC
Homo sapiens tumor protein p53 (p53) NM_000546.5 GGCCCACTTCACCGTACTAA GTGGTTTCAAGGCCAGATGT
Homo sapiens RB transcriptional
corepressor 1 (RB1)
NM_000321.2 TGCATGGCTCTCAGATTCAC AGTTGGTCCTTCTCGGTCCT
Homo sapiens E2F transcription
factor 1 (E2F1)
NM_005225.3 TGTGCATGAGTCCATGTGTG GGCCGAAAGTGCAGTTAGAG




Homo sapiens telomerase reverse
transcriptase (hTERT)
NM_198253.3 GCTAGTGGACCCCGAAGG CCTCCCTGACGCTATGGTT
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The employment of these established parameters for a
second transduction of T-MSCs with hTERT enabled us to
obtain a small population of hTERT-transduced T-MSCs,
which were named as immortalized MSCs (iMSCs). In our
system, hTERT transduction is less efficient than SV40LT
transduction, which is probably due to the fact that the
hTERT plasmid is longer, and thus Phoenix cell transfection
efficiency is reduced. It took 2-4 weeks for hygromycin-
selected iMSCs to grow enough to be trypsinized and
expanded but, after that, all the four generated iMSC lines
(three OA and one non-OA lines, experiment 7) showed high
proliferation rates.
3.2. Optimization of VPA Concentration. Cell Counting Kit-8
(CCK-8) was employed to determine the optimal VPA
concentration for transgene expression induction in MSCs.
Taking into account that absorbance is proportional to cell
population size, it was observed that the cell population
was reduced after spinoculation in a very variable way
(between 16% and 60%). This reduction was also observed
in the cells that have been centrifuged without virus addi-
tion. After three-day incubation with different concentra-
tions of VPA, little changes in cell population were
observed (p value = 0:5615). After puromycin selection, a
critical decrease of cell population size was noticed in all
cases aside from 0.5mM and 2mM VPA previous treat-
ments, in which this decrease was less severe. However,
no significant differences were found between groups after
treatment with different concentrations of VPA
(p value = 0:7886) or after selection (p value = 0:0700). Absor-
bance measurements (1) before spinoculation, (2) after spino-
culation, (3) after three-day incubation with 0.5-5mM VPA,
and (4) after puromycin selection, are shown in Supplemen-
tary Table S1. Differences between these measurements
before and (1) after spinoculation, (2) after VPA treatment,
and (3) after puromycin selection, are represented as the
percentage reduction of population in Figure 2.
3.3. Testing SV40LT and eGFP-hTERT Nuclear Expression in
Transduced MSCs. In order to prove that iMSCs were
properly transduced and expressed both transgenes,
SV40LT and GFP (fused to hTERT) immunostaining was
performed. Expression of both transgenes was detected in
the nuclei of iMSC#6, iMSC#8, iMSC#9, and iMSC#10.
SV40LT exhibited a “nucleolar exclusion” expression pat-
tern, while eGFP-hTERT showed a more variable pattern,
with differences in intensity and location, including strong
nucleolar signals and some more diffuse nucleoplasmic
signals (Figure 3). Furthermore, SV40LT and hTERT
expression was present in all the four iMSC lines and
absent in the primary MSCs from which they were
derived, as measured by qPCR. The REL of SV40LT in
iMSC#6, iMSC#8, iMSC#9, and iMSC#10 were 2:713 ±
0:254, 0:986 ± 0:184, 1:000 ± 0:088, and 0:646 ± 0:061,
respectively, and non-detected in primary MSCs, while
the REL of hTERT were 2:676 ± 0:149, 4:392 ± 0:655,
1:000 ± 0:073, and 0.029± 0.002 in iMSC#6, iMSC#8,
iMSC#9, and iMSC#10, respectively, 0:005 ± 0:001 in
MSC#10 and non-detected in MSC#6, MSC#8, and MSC#9
(Figure 4(a)).
3.4. Analysis of Morphology and Proliferative Capacity of
Transduced MSCs. Immortalized MSCs displayed a
fibroblast-like cell morphology (Figure 4(b)) characteristic of
MSCs. iMSCs showed more prominent nucleoli and less cyto-
plasm than T-MSCs (Figure 4(c)) and primary MSCs at the
4th passage (Figure 4(d)). OA and aged non-OAMSC cultures
at the 4th passage presented 60% of cells acquired large and
flat morphology (Figure 5(c)) and expressed senescence-
associated β-galactosidase (Figures 5(e) and 5(f)), while
iMSCs retained their size and fibroblast-like morphology and
showed almost no β-galactosidase activity after more than
40 passages (Figures 5(a)–5(d)), being the percentage of β-
galactosidase-positive cells 2:5 ± 1:1% for iMSC#6, 0:5 ± 0:1
% for iMSC#8, 0:8 ± 0:2% for iMSC#9, and 2:4 ± 0:8% for
iMSC#10 (Figure 5(f)). Regarding β-galactosidase activity, a
significant difference was found between iMSC lines and pri-
mary MSCs (p value < 0.0001).
The average of generation time for iMSCs was 2.0 days
for iMSC#6 between passages 20 and 70, 1.9 days for iMSC#8
between passages 10 and 50, 2.3 days for iMSC#9 between
passages 10 and 50, and 2.0 days for iMSC#10 between pas-
sages 10 and 35. In comparison, it was nearly 5.0 days in T-
MSC#6 between passages 7 and 13 and almost 20.0 days in
primary MSC#6 at the 4th passage. Immortalized MSCs #6,
#8, #9, and #10 were grown over 100 generations for more
than six months and continue to grow in culture. Regression
analysis showed a constant proliferation rate, with coefficient
of multiple correlation ðRÞ > 0:99 and p value < 0.00005 for
all four iMSC lines (Figure 6). Regarding generation time,
no significant differences were found between iMSC lines
(p value = 0:2).
3.5. Testing Maintenance of MSC Surface Marker Expression
in Transduced MSCs. The expression of five MSC-positive
(CD29, CD44, CD73, CD90, and CD105) and two negative
(CD34 and CD45) surface markers was analysed in primary
MSCs, T-MSCs, iMSCs, and in the 3a6 immortalized human
MSC line. In all cases, >90% of the cells were positive for
CD29, CD44, CD73, and CD90, except in T-MSC#8, T-
MSC#9, and T-MSC#10 (86%, 70%, and 85% positive for
CD73). Positivity for CD105 expression was more variable,
reducing its expression from 85% to 74% in primary
MSC#6 to iMSC#6 and from 92% to 38% in iMSC#8. Its
expression in primary MSC#9 and iMSC#9 was 37-44% but
72% in T-MSC#9. In primary MSC#10, T-MSC#10, and
iMSC#10, CD105 positivity was 76-74%, but it was raised
to 82% in higher passage iMSC#10. T-MSCs, iMSCs, and
3a6 cells lacked CD34 expression while primary MSC#6
and MSC#8 were almost 10% CD34 positive. In all cases,
<3% of the cells were positive for CD45 (Table 4).
3.6. Testing Maintenance of MSC Multipotency in
TransducedMSCs. In order to investigate if transducedMSCs
retained multipotency, primary MSC#6 (6th passage), T-
MSC#6 (12th passage), iMSC#6 (20th and 65th passages),





















































































































































































Figure 2: Percentage of cell population reduction (1) after spinoculation (p value = 0:1395), (2) after three-day incubation with 0.5 (a), 1 (b), 2
(c), 3 (d), or 5 (e) mMVPA (p value = 0:5615), and (3) after puromycin selection (p value = 0:0700) of SV40LT-transduced MSCs (f), inferred
from percentage difference between absorbance measurements employing CCK-8 (measure wavelength: 450 nm; reference wavelength:
650 nm). The error bars represent the standard deviation of measurements for three different MSC cultures (n = 3).
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cultured under osteogenic and adipogenic differentiation
conditions.
3.6.1. Osteogenesis. Primary MSC#6, T-MSC#6, and iMSCs
were able to differentiate into the osteogenic lineage after
21 days of induction, as shown by calcium phosphate
deposits stained in red with Alizarin Red. The lower mineral-
ization area after osteogenic induction was detected in pri-
mary MSC#6 (Figure 7(a)). The mineralized area extension
was twofold in T-MSC#6 (Figure 7(b)) and fourfold in
iMSC#6 (Figure 7c()) compared to MSC#6. 143B osteosar-
coma cell line (ATCC CRL-8303) was employed as a positive
mineralization control for osteogenic differentiation experi-
ments (Figure 8(c)). Furthermore, T-MSC#6 (11th passage),
iMSC#6 (25th passage), iMSC#9 (50th passage), and
iMSC#10 (40th passage) were cultured under chondrogenic
differentiation conditions, and iMSC#6 (60th passage),
iMSC#9 (50th passage), and iMSC#10 (40th passage) were
also induced to differentiate towards the bone through endo-
chondral ossification (Figure 7).
Mesenchymal cell lines iMSC#8 (Figure 8(a)) and
iMSC#9 (Figure 8b) showed equal mineralization capacity
to iMSC#6 and to 143B osteosarcoma cell line (Figure 8(c)).
However, the osteogenic-related genes Runx2, Sp7 (Osterix),
and Osteocalcin (OCN) were not upregulated in iMSC#6 cul-
tured in osteogenic medium compared to basal medium
(Figure 8(d)). Conversely, in iMSC#8, all the three genes
tested were upregulated after osteogenic induction, especially
the late osteogenic marker OCN (Figure 8(e)). In iMSC#9,
only OCNwas upregulated (Figure 8(f)). Due to this variabil-
ity between iMSC lines, no significant differences in Runx2,
Sp7, and OCN expression were found between osteogenically
induced (OM) and control (BM) iMSCs (p value > 0.05).
When comparing the expression in the three cell lines after
osteogenic induction, iMSC#8 showed the highest expression
of the three osteogenic markers.
iMSC#6, iMSC#9, and iMSC#10 were also able to differ-
entiate into the osteogenic lineage after induction in three-
dimensional cell culture. iMSC#6 and iMSC#9 presented a
threefold increase of Alizarin Red staining intensity (mea-
sured as OD) after differentiation in comparison with
20%FBS/DMEM control (Figures 9(a)–9(d)). In contrast,
iMSC#10 presented the same intensity after osteogenic
induction than culturing in 20%FBS/DMEM, as a result of
the high mineralization of control sample (Figure 9(e) and
9(f)). All iMSCs presented higher Von Kossa staining inten-
sities after osteogenic differentiation in comparison with
respective controls (Figures 9(g)–9(l)). Proteoglycans were


















Figure 3: SV40LT and eGFP-hTERT immunostaining of iMSC#6 (a–d), iMSC#8 (e–h), iMSC#9 (i–l), and iMSC#10 (m–p). SV40LT is
showed in red, eGFP-hTERT is showed in green, and Hoechst staining is showed in blue. Both nucleoli exclusion of SV40LT and nucleoli
association of hTERT are pointed with white arrows. Scale bar: 50μm.
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not detected in iMSC aggregates after neither osteogenic
induction nor culturing in 20%FBS/DMEM for five weeks
(Figures 9(m)–9(r)), in contrast to chondrogenic-induced
iMSCs (Figures 10(a) and 10(c)). No significant increase or
decrease of collagen fiber amount was detected after differen-
tiation in comparison with five-week culturing in
20%FBS/DMEM (Figures 9(s)–9(x)).
3.6.2. Adipogenesis. Primary MSC#6 showed the highest
potential to differentiate into the adipogenic lineage after 21
days of induction, as shown by intracellular lipid droplets
stained in red with Oil Red O (Figure 11(a)). T-MSC#6
showed a 50% reduction of the stained area in comparison
with primary MSC#6, and few preadipocytes could be identi-
fied (Figure 11(b)). iMSC#6 retained the adipogenic differen-
tiation potential, but the preadipocytes formed, though
clearly identifiable, were less mature than those formed by
primary MSC#6 and contained smaller lipid vacuoles
(Figure 11(c)). Accordingly, iMSC#6 showed a 70% reduc-
tion of the stained area in comparison with primary
MSC#6. Of note, positive Oil Red O staining was observed
in T-MSC#6 (Figure 11(e)) and also in iMSC#6
(Figure 11(f)) after culturing in 20%FBS/DMEM, suggesting
spontaneous adipogenic differentiation.
Cell line iMSC#8 showed a percentage of Oil Red O-
stained area similar to T-MSC#6 (Figure 12(a)), while
iMSC#9-stained area was equal to iMSC#6 (Figure 12(b)).
The reduction of the adipogenic potential from primary
MSC#6 to iMSC#6 was supported by gene expression analy-
sis, which showed reduced expression of the adipogenic
markers adiponectin (APN) and FABP4 (Figure 12(c)).
When comparing the expression of the three cell lines
after adipogenic induction, iMSC#6 showed the lowest
expression of both adipogenic markers, and iMSC#8
showed the highest adipogenic potency (Figure 12(d)).
Expression of APN and FABP4 was not detected in cells
cultured in basal medium (BM).
3.6.3. Chondrogenesis. Both T-MSC#6 and iMSC#6 were able
to differentiate into the chondrogenic lineage after 21 days of
induction in three-dimensional cell culture. Histological
staining indicated the presence of proteoglycans (stained
orange by Safranin O staining; Figures 13(a) and 13(b)) and
collagen (stained blue by Masson’s Trichrome staining;
Figures 13(c) and 13(d)) in the extracellular matrix of
the aggregates. Strong aggrecan immunostaining was
observed in both T-MSC#6 (Figure 13(e)) and iMSC#6
(Figure 13(f)) aggregates, being almost twofold more
intense in iMSC#6. Type II collagen immunostaining was
intense in T-MSC#6 aggregates (Figure 13(g)) but faint
in iMSC#6 (Figure 13(h)), immunostaining being twelve-
fold more intense in T-MSC#6 aggregates. Aggregates
had heterogeneous shapes and sizes, as can be appreciated
in the micrographs (Figure 13).
When compared to respective controls, both iMSC#6 and























Figure 4: SV40LT and hTERT normalized expression in immortalized MSCs (iMSCs) and primary MSCs (a), shown as mean ± standard
error for each group. Phase-contrast microscopic images of iMSCs (b), T-MSCs (c), and primary MSCs (d). Magnification 10x.
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chondrogenic differentiation was induced, as shown by
orange staining of proteoglycans by Safranin O staining
(Figures 10(a)–10(d)). Greater amount of collagen was also
detected in chondrogenic-induced iMSCs, as shown by blue
staining of collagen fibers by Masson’s Trichrome staining
(Figures 10(e)–10(h)). Aggrecan immunostaining was almost
fourfold and twofold more intense in chondrogenic-induced
iMSC#6 and iMSC#9, respectively, when compared to the
controls (Figures 10(i)–10(l)). When comparing iMSC#6
and iMSC#9, iMSC#6 showed the most intense aggrecan
immunostaining after chondrogenic induction, correlating
with the highest amount of proteoglycans detected.
Chondrogenic-induced iMSC#10 aggregates were too small
to allow the performance of histological techniques, and
therefore could not be analysed. iMSC#8 was unable to form
aggregates by the hanging drop method employed.
3.7. Testing Colony Formation Ability and Oncogenic
Potential of Transduced MSCs. A clonogenic assay was per-
formed to assess the colony formation ability of iMSCs. After
one week, all iMSC lines were able to form colonies. In addi-
tion, a soft agar assay was performed to assess oncogenic
potential of iMSCs. After 14 days, two out of four iMSC lines
formed colonies in soft agar. Representative micrographs are
shown in Figure 14. iMSC#6 formed colonies with wide
intercellular spaces (Figure 14(a)) and was not able to grow
in soft agar (Figure 14(b)). Conversely, iMSC#8 formed more









































Figure 5: Phase-contrast microscopic images of the senescence-associated ß-galactosidase activity stained iMSC#6 (a), iMSC#8 (b), iMSC#9
(c), iMSC #10 (d) and primary MSCs (e). Magnification: 10x. Percentage of positive ß-galactosidase-stained, senescent cells, for each
population (f). The error bars represent the standard deviation of measurements for three passages of each iMSC line (n = 3). Significant
difference was found between iMSC lines and primary MSCs (p value < 0.0001).
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agar (Figure 14(d)), as well as iMSC#9 (Figures 14(e) and
14(f)). iMSC#10 presented a phenotype similar to iMSC#6,
forming uncompacted colonies (Figure 14(g)) and being
unable to grow in soft agar (Figure 14(h)).
As for tumor-related gene expression, no significant
differences were found between iMSCs and primary MSCs
(p value > 0.05). However, some trends were observed.
The REL of the tumor suppressor p53 was upregulated




























Figure 6: Number of generations accumulated by iMSC#6, iMSC#8, iMSC#9, and iMSC#10, calculated as ðlogNf – logNiÞ/log2 (where Nf is
the final cell population, Ni is the number of cells in the inoculum, and log is the natural logarithm), facing days in culture. R > 0:99 and
p value < 0.00005 for all four iMSC line growth curves.
Table 4: Flow cytometric analysis of mesenchymal markers CD29, CD44, CD73, CD90, and CD105 and the hematopoietic markers CD34
and CD45; 105 events were acquired for each sample.
Cells Passage CD29 CD44 CD73 CD90 CD105 CD34 CD45
MSC#6 4 99.2% 99.6% 98.4% 96.2% 85.2% 9.9% 0.1%
T-MSC#6 (4 + 3) 99.0% 98.9% 96.2% 99.1% 82.3% 1.5% 0.4%
iMSC#6 (4 + 9 + 6) 99.2% 98.9% 98.0% 98.3% 81.0% 0.1% 0.0%
iMSC#6 (PD > 100) (4 + 9 + 44) 98.2% 98.9% 97.1% 99.5% 73.8% 0.0% 0.0%
MSC#8 4 98.6% 99.4% 98.3% 98.9% 91.6% 9.8% 0.0%
T-MSC#8 (4 + 4) 93.9% 92.7% 86.3% 95.0% 46.0% 0.4% 0.1%
iMSC#8 (4 + 2 + 15) 99.9% 99.6% 99.6% 99.0% 42.1% 0.0% 0.1%
iMSC#8 (PD > 100) (4 + 2 + 32) 98.8% 98.8% 98.7% 99.1% 38.4% 0.4% 0.2%
MSC#9 4 96.3% 97.0% 95.5% 96.2% 42.2% 0.6% 0.3%
T-MSC#9 (4 + 4) 98.4% 97.9% 69.6% 95.5% 71.7% 0.1% 0.2%
iMSC#9 (4 + 2 + 15) 98.4% 95.7% 97.3% 92.5% 37.3% 0.2% 0.4%
iMSC#9 (PD > 100) (4 + 2 + 35) 98.8% 98.4% 98.7% 99.3% 44.6% 0.9% 0.9%
MSC#10 4 97.9% 97.5% 93.0% 98.7% 76.0% 0.6% 0.3%
T-MSC#10 (4 + 2) 98.5% 98.1% 85.4% 97.4% 73.7% 0.0% 1.0%
iMSC#10 (4 + 3 + 14) 98.9% 98.9% 92.8% 99.1% 74.0% 0.4% 0.2%
iMSC#10 (PD > 100) (4 + 3 + 31) 98.4% 98.8% 93.9% 98.4% 82.4% 0.3% 2.7%
3a6 (x + 30) 99.2% 99.8% 98.0% 98.3% 61.7% 0.1% 0.0%
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in three out of four iMSC lines, iMSC#6 (0:599 ± 0:049),
iMSC#9 (0:599 ± 0:023), and iMSC#10 (0:766 ± 0:163) in
comparison with the REL of their respective untransduced
counterparts (0:017 ± 0:001, 0:286 ± 0:034, and 0:268 ±
0:036, respectively), with a REL lower than that of 143B
(1:000 ± 0:059), while in iMSC#8 it was downregulated
(0:310 ± 0:076 versus 0:963 ± 0:054 in MSC#8). Similarly,
the REL of the tumor suppressor Rb was higher in three
of the iMSC lines, iMSC#6 (1:424 ± 0:064 versus 0:187 ±
0:006 in MSC#6), iMSC#8 (2:540 ± 0:407 versus 1:682 ±
0:260 in MSC#8), and iMSC#10 (2:412 ± 0:452 versus
0:874 ± 0:004 in MSC#10), but lower in iMSC#9
(1:371 ± 0:113 versus 1:892 ± 0:118 in MSC#9).
The REL of the transcription factor E2F1, a positive reg-
ulator of cell proliferation, was also higher in three of the
iMSC lines, iMSC#6 (3:745 ± 0:130 versus 0:151 ± 0:014 in
MSC#6 T-MSC#6 iMSC#6


































Figure 7: Alizarin Red staining of primary MSC#6, T-MSC#6, and iMSC#6 after 21 days of osteogenic induction (a–c) or culture in









































































































Figure 8: Alizarin Red staining of iMSC#8 (a), iMSC#9 (b), and 143B osteosarcoma cell line (c) after 21 days of osteogenic induction.
Percentage of Alizarin Red-stained area for each sample is shown (scale bar: 100μm; magnification: 10x). Osteogenesis-related gene
expression after culturing in basal medium (BM) and osteogenic medium (OM) is shown for iMSC#6 (d), iMSC#8 (e), and iMSC#9 (f)
(p value > 0.05).
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MSC#6), iMSC#9 (2:819 ± 0:270 versus 0:525 ± 0:028 in
MSC#9), and iMSC#10 (1:653 ± 0:239 versus 0:693 ± 0:051
in MSC#10), and lower in iMSC#8 (2:505 ± 0:304 versus
4:213 ± 0:138). Contrariwise, the protooncogene H-RAS
was only upregulated in iMSC#6 (REL 2:612 ± 0:143 versus
0:255 ± 0:025 in MSC#6) but downregulated in iMSC#8
(0:662 ± 0:140 versus 6:845 ± 0:383 in MSC#8) and iMSC#9
(0:785 ± 0:083 versus 3:959 ± 0:082 in MSC#9) and main-
tained in iMSC#10 (1:352 ± 0:247 versus 1:464 ± 0:102 in
MSC#10) (Figure 15).
4. Discussion
MSCs derived from aged donors are prone to senesce during
in vitro culture but could acquire an unlimited proliferation








































































































































0.312 ± 0.038 0.227 ± 0.0250.149 ± 0.025
0.316 ± 0.022 1.571 ± 0.0650.316 ± 0.019 0.148 ± 0.021 0.154 ± 0.0090.008 ± 0.002
0.0 ± 0.0% 0.0 ± 0.0%
0.0 ± 0.0%0.0 ± 0.0%0.0 ± 0.0%
8.4 ± 1.7% 22.8 ± 1.9%17.6 ± 1.1%
21.9 ± 2.5%37.1 ± 1.6%5.1 ± 1.7%
0.0 ± 0.0%
Figure 9: Alizarin Red staining (a–f), Von Kossa staining (g–l), Safranin O staining (m–r), and Masson’s Trichrome staining (s–x) of
iMSC#6, iMSC#9, and iMSC#10 after 3D osteogenic induction or five-week culturing in 20%FBS/DMEM) (scale bar: 100 μm;



































33.0 ± 2.6% 72.9 ± 3.9% 0.746 ± 0.0804.0 ± 0.9%
1.3 ± 1.1%0.8 ± 0.7%
28.5 ± 2.6%
4.8 ± 0.7%8.2 ± 1.8%
0.267 ± 0.030
0.200 ± 0.058 0.136 ± 0.005
Figure 10: Histochemical and immunohistochemical staining of iMSC#6 and iMSC#9 after 21 days of chondrogenic induction or culturing in
20%FBS/DMEM: Safranin O staining (a–d), Masson’s Trichrome staining (e–h), and aggrecan immunostaining (i–l) (scale bar: 100μm;
magnification: 10x). Quantification is shown for each sample as percentage of stained area or intensity (optical density).
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telomere shortening are repressed by transduction of immor-
talization genes [3, 15, 18]. Retroviral transduction of slow-
dividing adult human cells is an ineffective process and
requires the use of enhancing methods such as spinoculation,
employment of chemical adjuvants, and addition of trans-
gene expression inductors, which give better results when
adapted to the particular transduction system [20, 37]. The
method here proposed is suitable for transduction of aged
MSCs and other types of adult human cells and allows
their immortalization. For its optimization, several varia-
tions were assayed, including SV40LT and hTERT cotrans-

































Figure 11: Oil Red O staining of primary MSC#6, T-MSC#6, and iMSC#6 after 21 days of adipogenic induction (a–c) or culture in



















































































Figure 12: Oil Red O staining of iMSC#8 (a) and iMSC#9 (b). Percentage of Oil Red O-stained area for each sample is shown (scale bar:
100μm; magnification: 10x). Adipogenesis-related gene expression after culturing in adipogenic medium is shown comparing MSC#6, T-
MSC#6, and iMSC#6 (c) and comparing iMSC#6, iMSC#8, and iMSC#9 (d). APN and FABP4 expression was not detected in cells
cultured in basal medium.
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of packaging cells for retrovirus production, two speeds
and three time-points of centrifugation for spinoculation,
and five different concentrations of VPA, an inductor of
transgene expression (Table 2).
In our system, spinoculation of primary MSCs with
hTERT retrovirus triggered general cell death, which may be
due to apoptosis induction by hTERT overexpression, a phe-
nomenon that has been observed in primary cells with a short
lifespan [16]. Even when employing SV40LT retrovirus, cell
survival to spinoculation at 1000 ×g was low, which may be
attributed to centrifugation-induced stress, as lowering centri-
fugation speed to 800 ×g remarkably improved cell survival.
The maximum optimal spinoculation speed depends on cell
type [23]; at higher speeds, centrifugation-induced stress
might cause damage to the cells and make them more suscep-
tible toHDMB toxicity [35]. However, lowering centrifugation
time below 45minutes did not improve cell survival and was
unfavourable for infection, in accordance with the results
obtained by others authors [33, 34].
Six lines of SV40LT-transduced MSCs (T-MSCs) were
generated employing the chosen parameters for spinocula-
tion (800 ×g and 45minutes) and SV40LT retrovirus pro-
duced by Phoenix cells during 48-hour incubation at 32°C.
Employing hTERT retrovirus and these same parameters
for T-MSC transduction, hTERT-induced apoptosis was
not observed, which is in accordance with previous reports
[16]. In this manner, four different lines of immortalized
MSCs (iMSCs) were obtained.
Because of their polyanionic nature, viral DNA interacts
with positively charged histones in the nucleus, resulting in
a loss of gene expression, which may be a cellular defence
mechanism against viruses. However, these gene silencing
can be reversed by histone acetylation through the addition
of histone deacetylase inhibitors such as VPA [51, 52]. Cell
viability measurements performed to optimize VPA concen-
tration showed that MSC population was reduced after spi-
noculation in a very variable way. This reduction may be

























Figure 13: Histochemical and immunohistochemical staining of T-MSC#6 and iMSC#6 aggregates after 21 days of chondrogenic induction:
Safranin O staining of T-MSC#6 (a, 20x) and iMSC#6 (b, 10x); Masson’s Trichrome staining of T-MSC#6 (c, 20x) and iMSC#6 (d, 10x);
aggrecan immunostaining of T-MSC#6 (e, 20x) and iMSC#6 (f, 10x); and type II collagen immunostaining of T-MSC#6 (g, 20x) and























Figure 14: Crystal violet staining to assess the clonogenic potential of iMSC lines (a, c, e, g) and soft agar assay to assess their oncogenic
potential (b, d, f, h). Scale bar: 1mm.
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also observed when no viruses were added. Our results indi-
cated that VPA do not exert any negative effect on cell viabil-
ity, but a negative effect on proliferation while present in the
culture medium cannot be discarded.
After puromycin selection of T-MSCs, cell population
size decreased for all VPA concentrations tested. However,
MSCs treated with 0.5mM and 2mM VPA showed the
most moderate reduction of cell population. We hypothe-
sized that it can be related to differences in spinoculation
efficiency caused by the particular position of each well
of the dish when centrifuging, which, to the best of our
knowledge, have never been reported. It is also important
to note that during transduction, transgenes are being
inserted in different regions of the genome, with different
levels of epigenetic modifications, in each transduced cell.
Therefore, each cell may respond differently to the same
concentration of VPA [53], probably contributing to the
variability observed.
Finally, 2mM VPA was established as the optimal con-
centration above 0.5mM based on our previous observations
and its greater similarity to concentrations established as
optimal for other transduction systems [37, 40]. For exam-
ple, Cervera et al. [37] reported that the addition of
3.36mM VPA four hours posttransfection was the optimal
concentration to enhance transient gene expression while
increasing cell viability in HEK-293 cells [37], and Fang
et al. [38] employed a concentration of 3.5mM VPA to
increase the production of recombinant antibodies with sim-
ilar results [38]. In addition, Joglekar et al. [51] showed that
VPA enhanced gene expression from lentiviral vectors in
human hematopoietic stem cells in a concentration-
dependent manner, with 1.5mM being significantly superior
to 0.5mM [51].
However, Jäger et al. [40] observed a reduction of cell
proliferation and viability along with the increase in recombi-
nant antibody production in HEK-293 cells after treating
with 3.75mM VPA [40], and Wulhfard et al. [39] also
observed that 3.75 or 5mM VPA induced a concentration-
dependent cell growth arrest in CHO cells, despite increasing
recombinant antibody yields [39]. All these data indicated
that relatively high VPA concentrations (between 1.5 and
3.5mM) may enhance transgene expression more efficiently,
but at higher concentrations (over 3.5mM), the deleterious
effects over cells overcome the beneficial effects over trans-
gene expression.
Immunofluorescence of iMSC#6, iMSC#8, iMSC#9, and
iMSC #10 showed that, in their nuclei, SV40LT was located
in the nucleoplasm and excluded from the nucleoli, which
occurs in other SV40LT-transduced cell lines [45]. Catalyti-
cally active telomerase intranuclear localization is regulated
by cell cycle stage, being sequestered at nucleoli in the G1
phase and released to the nucleoplasm in the S/G2 phase.
Although it has been reported that SV40LT transduction of
primary cells promotes the release of telomerase from the
nucleoli to the nucleoplasm, in these iMSCs, eGFP-hTERT
seems to be preferentially associated with the nucleoli
(Figure 3), suggesting that they have not underwent malig-





















































































































































































Figure 15: Normalized levels of expression of the tumor-related genes p53, Rb, E2F1, and H-RAS in primary MSCs, immortalized MSCs
(iMSCs), and the osteosarcoma cell line 143B (p value > 0.05).
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However, iMSC#8 and iMSC#9 were able to form colo-
nies in soft agar in spite of the H-RAS downregulation in
both cell lines after immortalization. This ability may be
related to oncogenic alterations present in the primary MSCs
#8 and #9, which expressed levels of H-RAS much higher
than the osteosarcoma cell line 143B. Nevertheless, immor-
talized MSCs transduced with protooncogenes can eventu-
ally become tumorigenic, making them useless for clinical
approaches, but not for research purposes. Oncogenic muta-
tions may arise during passaging of iMSCs [54], and iMSCs
seeded at low densities during long periods of time have been
reported to be tumorigenic [55].
Growth arrest is orchestrated by the tumor suppressors
p53 and Rb. In response to stress or DNA damage, p53 is
phosphorylated and liberated from its binding to E3 ubiqui-
tin ligase Mdm2, hence activating the senescence pathways.
During quiescence, unphosphorylated Rb proteins control
cell proliferation by binding and inhibiting E2F transcription
factors, therefore blocking cell cycle progression. SV40LT
binds to both these proteins, allowing the overcoming of
senescence and releasing the activity of E2F transcription fac-
tors [54, 56]. Since SV40LT inhibition of p53 and Rb occurs
at the protein level, the mRNA coding for these proteins
may accumulate in SV40LT-transduced cells without effec-
tively triggering senescence. In fact, higher levels of p53 and
Rb in iMSCs do not correlate with lower levels of E2F nor
have any effect over cell proliferation. Other tumor suppres-
sor genes, such as PTEN, have also been found to be upregu-
lated after MSC immortalization [57].
We found that MSC morphology did not change after
transduction of immortalization genes, as has been previ-
ously reported by others [9, 14, 19]. As for their morphology,
iMSCs were more similar to young MSCs than aged MSCs,
retained the ability to grow until reaching a confluent mono-
layer, and lacked granular content related to lisosomal
senescence-associated β-galactosidase activity (≤5.0% of cells
were β-galactosidase positive), unlike late-passage primary
OA MSCs, as has also been observed in other immortalized
MSC lines [14, 17].
All the four iMSC lines showed a higher proliferation rate
than T-MSC#6 (~2 and 5 days, respectively), which showed
likewise a higher proliferation rate than primary MSC#6.
Faster proliferation has been often observed after SV40LT
transduction [9] but has not been attributed to hTERT alone
[14], yet the combination of SV40LT or p53 knockdown with
hTERT overexpression can exert a synergistic effect in
improvingMSC growth rate [17, 19]. From the initial passage
to senescence, MSCs are not able to carry out more than 30-
40 [5, 12, 14], while immortalized MSCs are able to reach
more than 200 PDs [12, 14]. Up to now, all the four iMSC
lines have undergone more than 100 PDs and continue to
proliferate in vitro without any sign of senescence.
As for phenotypic characterization, the mesenchymal
surface markers CD29, CD44, CD73, and CD90 were highly
expressed in primary MSCs, T-MSCs, and iMSCs, while
CD105 expression was reduced with either subculturing or
transduction in iMSC#6 and iMSC#8, and also showed vary-
ing levels of expression iMSC#9. However, these markers are
also expressed by terminally differentiated MSCs [58] and
other cells such as fibroblasts [2, 59], and thus, they may
not be very reliable markers to identify undifferentiated
MSCs, although traditionally established as a necessary
requirement for defining them [60].
Even though it has been generally reported that the high
expression of CD29, CD44, CD73, CD90, and CD105 is
maintained in MSCs regardless of passage number [5, 18],
some authors have noticed the downregulation of some of
these markers during in vitro expansion [61, 62] and due to
particular culture conditions [63]. Their expression seems
to be mainly preserved after immortalization [12, 14, 19],
although CD105 decrease following SV40LT and hTERT
transduction has also been reported [17] and has also been
observed in the E6/E7 and hTERT-transduced 3a6 cell line.
Of notice, CD105 upregulation has been associated with late
passages and cellular senescence [64]. The reason of its
decrease in iMSCs is difficult to elucidate as in vitro
culture-related and immortalization-related effects are
undistinguishable.
ImmortalizedMSCs have often been reported to be able to
differentiate towards osteoblasts and adipocytes [12, 9, 14, 19],
but transduction of SV40LT and hTERT together has resulted
in immortalized MSCs without adipogenic [18] or osteogenic
[17] potential. The adipogenic potential has been described to
be progressively reduced throughout in vitro expansions in
spite of immortalization [18, 65]. Chondrogenic potential of
immortalized MSCs has seldom been assayed [9, 17, 18],
and when investigated, has often shown to be limited [12,
14, 66, 67], with scarce exceptions [19].
iMSC#6 differentiation potential seems to have varied as
a result of either immortalization or passaging. Osteogenic
potential was higher in T-MSC#6 than in primary MSC#6,
and even greater in iMSC#6. On the contrary, T-MSC#6
and iMSC#6 showed reduced adipogenic potential in com-
parison with MSC#6. Osteogenic and adipogenic potential
of iMSC#8 and iMSC#9 were similar to that of iMSC#6,
except for the higher adipogenic potential of iMSC#8. Chon-
drogenic potential of T-MSC#6, iMSC#6, and iMSC#9 was
evidenced by their ability to produce an extracellular matrix
containing collagen and aggrecan. However, notably higher
amount of type II collagen was detected in T-MSC#6 aggre-
gates, perhaps indicating that iMSCs produced a lower qual-
ity cartilage-like tissue.
The lower quality of cartilage-like tissue produced by
iMSC#6 and iMSC#9 in comparison with T-MSC#6 could
be suggested as a result of its lower CD105 positivity, as it
is part of the TGF-ß receptor complex. However, it has been
noted that CD105+ MSCs have no superior chondrogenic
potential than the CD105- ones [68], even though it is still
controversial [69]. It has also been stated that, as a counter-
part of decreased chondrogenic potential, CD105- MSCs
show increased osteogenic potential [69] as a result of supe-
rior adhesion andmineralization efficiency [70], which might
be related to the superior osteogenic potential of iMSCs. Nev-
ertheless, surface marker expression does not necessarily
reflect the functional capacities of MSC [63], and the inferior
osteogenic potential of primary MSC#6 may be also due to
them being differentiated at the 6th passage, when cells are
expected to be aged [5, 71].
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The differentiation abilities of T-MSCs and iMSCs may
be derived from the potential of those MSCs effectively trans-
duced when spinoculations were performed [12], since those
cells, susceptible to infection and located on the parts of the
dish where less centrifugation-induced stress is exerted, are
arbitrary selected during spinoculation. Moreover, extensive
passaging may lead to the selection of those cells with higher
growth rates, altering thereby other properties of the cell
population, as multilineage differentiation potential [62]. It
is commonly accepted that osteogenesis is the default differ-
entiation pathway for MSCs [12, 72, 73] and the most com-
monly retained differentiation lineage at later passages [62,
72]. This osteogenic commitment may be responsible of the
high bone-related transcription factor expression detected
before osteogenic inducement of iMSCs.
In summary, we developed a method that combines
enhancement of retroviral transduction by spinoculation
and induction of transgene expression by VPA supplementa-
tion. This method allows immortalization of aged MSCs with
preservation of most mesenchymal features. However, it has
been noticed that either immortalization or passaging pro-
duced some alterations regarding CD105 expression and
multidifferentiation potential.
5. Conclusions
The aim of this study was to develop an easy and efficient
method for immortalization of slow-dividing cells, such as
aged MSCs. MSCs derived from aged and OA donors may
be immortalized by SV40LT and hTERT sequential trans-
duction employing the method we described. Immortaliza-
tion allows these cells to increase its proliferation rate and
to avoid senescence, while maintaining mesenchymal pheno-
type and multipotency.
The immortalized MSC lines generated by this method
have the ability to differentiate into the osteogenic lineage
both in two-dimensional and three-dimensional cultures,
and also into the adipogenic and chondrogenic lineages
with several levels of success. Therefore, iMSCs are
expected to be valuable tools for the bone and cartilage
regeneration research. Specifically, further analysis can
shed light about pathological differences in the field of
rheumatic diseases, as the cells can be derived from the
MSCs of aged and OA donors.
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